TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers

Hepatitis C Clinical Trial

Official title:

A Double-blind, Double-dummy, Randomized, 4-period Cross-over, Placebo- and Positive-controlled Study to Evaluate the Effect of TMC435 on the QTc Interval in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01269294
• Other study ID #: CR017491
• Secondary ID: TMC435-TiDP16-C1
• Status: Completed
• Phase: Phase 1
• First received: December 30, 2010
• Last updated: May 3, 2013
• Start date: January 2011
• Est. completion date: July 2011

Study information

• Verified date: May 2013
• Source: Tibotec Pharmaceuticals, Ireland
• Contact: n/a
• Is FDA regulated: No
• Health authority: Ireland: Irish Agriculture and Food Development Authority
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effect of TMC435 on the results of electrocardiograms (ECGs) in healthy volunteers. An electrocardiogram is an electric recording of the heart. TMC435 is being investigated for the treatment of chronic hepatitis C virus infection.

Description:

This is a double-blind, double-dummy, randomized, 4-period cross-over, placebo- and positive-controlled, Phase I study. This means neither the study doctor nor the participants know in which treatment session you will receive which active medication or matching placebo. Every participant will receive 4 treatment sessions (Treatments A, B, C and D) in a different order. The order in which you receive the treatment sessions is determined by chance, like tossing a coin. The purpose of the study is to evaluate the effect of TMC435 on the results of electrocardiograms (electric recording of the heart). Two dose regimens of TMC435 will be tested, ie, 150 mg once daily (the dose that will be given to patients) and 350 mg once daily (a dose higher than the one that will be given to patients), administered for 7 days. A single dose of 400 mg moxifloxacin will be used as a positive control to assess trial sensitivity. The trial population will consist of 60 healthy volunteers of which approximately 18 will be females. In each treatment, dummy capsules will be added in order to have the same number of capsules in each treatment. Treatment A will consist of 150 mg TMC435 once daily for 7 days (2 capsules of TMC435 and 2 capsules placebo on days 1-7, 1 placebo tablet for moxifloxacin on Day 7). Treatment B will consist of 350 mg TMC435 once daily for 7 days (4 capsules of TMC435 on Days 1-7, 1 placebo tablet for moxifloxacin on Day 7). Treatment C will consist of 400 mg moxifloxacin on Day 7 (4 capsules of placebo for TMC435 on Days 1-7, 1 moxifloxacin tablet on Day 7). In Treatment D only placebo will be given (4 capsules of placebo for TMC435 on Days 1-7, 1 placebo tablet for moxifloxacin on Day 7). There will be a washout period of at least 10 days between subsequent treatments. A pharmacogenomic blood sample (DNA sample, blood sample from which your genetic information can be analyzed) will be collected from all volunteers and will be analyzed upon observation of irregular electrocardiogram during the study. The purpose is to see if irregularities in the electrocardiogram can be linked to genetic variants. DNA samples may also be analyzed for additional genes related to pharmacokinetics (what the body does with the drug), pharmacodynamics (what the drug does to your body) or safety and tolerability of TMC435 during the study, as necessary. Two oral doses of TMC435 (150 or 350 mg) or placebo will be given once daily for 7 consecutive days. A single dose of moxifloxacin 400 mg will be administered orally on Day 7 in one of the treatment sessions only.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: July 2011
• Est. primary completion date: July 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Non-smokers for at least six months

• Have a body mass index of 18.0 to 30.0 kg per square meter

• Be healthy on the basis of physical examination, medical history, vital signs, and clinical laboratory tests performed at screening.

Exclusion Criteria:

• Use of disallowed therapies, including over-the-counter products and dietary supplements

• Any skin condition likely to interfere with ECG electrode placement or adhesion

• History or evidence of current use of alcohol or recreational or narcotic drug use

• Clinically relevant abnormality on ECG at screening or history of clinically relevant heart rhythm disturbances.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hepatitis C

Intervention

Drug:
• TMC435
2 capsules of 75 mg once daily for 7 days in Treatment A
• Placebo for TMC435
4 placebo capsules once daily for 7 days in Treatment C
• TMC435
2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B
• Placebo for TMC435
2 placebo capsules once daily for 7 days in Treatment A
• Moxifloxacin
1 tablet of 400 mg on Day 7 of Treatment C
• Placebo for moxifloxacin
1 placebo tablet on Day 7 of Treatments A, B and D
• Placebo for TMC435
4 placebo capsules once daily for 7 days in Treatment D

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Tibotec Pharmaceuticals, Ireland

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in QT/QTc interval for TMC435 therapeutic dose versus placebo		24-hour measurement on Day 7 of Treatment Session A and D	No
Primary	Change in QT/QTc interval for TMC435 supratherapeutic dose versus placebo		24-hour measurement on Day 7 of Treatment Session B and D	No
Secondary	RR interval, HR, PR interval, QRS interval and ECG morphology		1-hour predose measurement on Day 1 of every treatment session	No
Secondary	RR interval, HR, PR interval, QRS interval and ECG morphology		24-hour measurement on Day 7 of every treatment session	No
Secondary	Pharmacokinetics of 150 mg TMC435 once daily for 7 days		Predose on Day 1 of every treatment and on Days 5 and 6 of Treatments A and B. 24 hour profile on Day 7 of Treatment A and B	No
Secondary	Pharmacokinetics of 350 mg TMC435 once daily for 7 days		Predose on Day 1 of every treatment and on Days 5 and 6 of Treatments A and B. 24 hour profile on Day 7 of Treatment A and B	No
Secondary	Changes from baseline for electrocardiogram (ECG) and physical examination		During all treatment sessions: Daily safety ECG from Day -1 to Day 9 with on Day 1 and 7 an additional safety ECG at 5h timepoint plus at screening and follow-up visits. Physical examination at screening, on Day 8 and at the follow-up visits	No
Secondary	Number of participants with adverse events and severity of adverse events		From signing of informed consent onwards until last trial-related visit	No
Secondary	Changes from baseline and percentage of subjects with abnormal values for laboratory parameters		At screening, on Days -1, 1, 5, 8 of all treatment sessions and at the follow-up visits	No
Secondary	Changes from baseline and percentage of subjects with abnormal values for pulse and blood pressure		At screening, daily from Day -1 to Day 9 with a second measurement on Day 7 of all treatment sessions and at the follow-up visits	No
Secondary	Difference of QTc between moxifloxacin treatment and placebo treatment as a measure for trial sensitivity		On Day 7 of Treatment C and D, at the 2, 3, 4 and 5 hour timepoints	No